Trials / Conditions / Marginal Zone B-cell Lymphoma

Marginal Zone B-cell Lymphoma

15 registered clinical trials studyying Marginal Zone B-cell Lymphoma — 4 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma NCT07024147	Peking University Cancer Hospital & Institute	Phase 1
Recruiting	Study to Assess Clinical Characteristics and Outcome of Patients with Marginal Zone Lymphomas NCT06806488	IRCCS Azienda Ospedaliero-Universitaria di Bologna	—
Terminated	Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma NCT03919175	Massachusetts General Hospital	Phase 2
Recruiting	Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders NCT03314974	Masonic Cancer Center, University of Minnesota	Phase 2
Completed	UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep NCT02722668	Masonic Cancer Center, University of Minnesota	Phase 2
Terminated	Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies NCT02991898	Masonic Cancer Center, University of Minnesota	Phase 2
Recruiting	Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases NCT01962636	Masonic Cancer Center, University of Minnesota	N/A
Terminated	A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma NCT02914938	MEI Pharma, Inc.	Phase 1
Completed	Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL) NCT02433795	Seoul National University Hospital	Phase 2
Terminated	A Phase II Study of Doxycycline in Relapsed NHL NCT02086591	University of Rochester	Phase 2
Withdrawn	T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies NCT01163201	Masonic Cancer Center, University of Minnesota	Phase 1 / Phase 2
Completed	Bendamustine and Rituximab for the Treatment of Splenic Marginal Zone Lymphoma NCT02853370	International Extranodal Lymphoma Study Group (IELSG)	Phase 2
Completed	A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers NCT01460134	Celldex Therapeutics	Phase 1
Completed	Multicenter Phase II Study to Evaluate the Clinical Activity and the Safety Profile of Everolimus in Marginal NCT01164267	International Extranodal Lymphoma Study Group (IELSG)	Phase 2
Completed	Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Ritux NCT00783367	Abramson Cancer Center at Penn Medicine	Phase 2